Viome Life Sciences announced a $25 million internal Series D and the appointment of its new chief operating officer, Kal Raman.
Khosla Ventures, Marc Benioff, Bold Capital WRG Ventures and others participated in the round.
Raman joins Viome as COO after previously holding the position of senior vice president of non-media business, marketing and retail technology at Amazon and chief digital...
Viome Life Sciences announced it closed a $86.5 million oversubscribed Series C funding round, bringing its total raise to $175 million.
Bold Capital and Khosla Ventures participated in the round alongside existing and new investors.
The company also announced the launch of its Gut Intelligence Test in 200 CVS locations.
WHAT IT DOES
The company offers a total body intelligence test for users...
Viome Life Sciences announced Wednesday it had raised $54 million in a pre-Series C convertible funding round.
Participants in the round include existing investors Khosla Ventures, West River Group, Glico, Physician Partners and Bold Capital Group alongside new investor Ocgrow Ventures.
Viome said this latest investment brings its total capitalization to $125 million.
WHAT THEY DO
Viome is split...
Viome Life Sciences, maker of at-home tests for gut and immune system health, is expanding its partnership with global pharma company GlaxoSmithKline to research and potentially develop interventions for some cancers and autoimmune diseases.
The collaboration will allow the companies to study the connection between the gut microbiome and some chronic diseases, like autoimmune disorders. Viome...
Viome, maker of at-home test kits for gut, immune and cellular health, has received FDA breakthrough device designation for its mRNA analysis technology and artificial intelligence platform that detect early signs of oral cancer and throat cancer.
The FDA designation validates the technology used in Viome’s at-home Health Intelligence Test that analyzes users’ microbial, human and mitochondrial...
